Startup profile for Slingshot AI: latest funding, latest known valuation, total disclosed funding, investors, status, sources, and why the company is interesting. Part of the Venture Capital Tracker startup directory.

Startup profile · funding coverage

Slingshot AI funding, valuation and investors

Foundation models and consumer app (Ash) for AI mental-health support.

Keep track of Slingshot AI

Save this profile to your VCT watchlist for a quick return.

View watchlist

Funding, valuation & investors

Answer-first snapshot

Latest funding

Series A extension

$53M · July 2025

Latest known valuation

Not publicly disclosed

Total disclosed equity funding

$53M

Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.

Current status

private

series a · New York, New York

Investors in latest funding

Lead: Radical Ventures , Forerunner Ventures

Other: Andreessen Horowitz , Menlo Ventures

Sources: latest funding Last verified: 2026-07-25

Overview

Slingshot AI builds foundation models tailored for mental health and offers Ash, a consumer app for AI-guided emotional support. Founded by Neil Parikh (Casper co-founder) and Daniel Cahn, the company raised ~$30M Series A in August 2024 led by Andreessen Horowitz with Menlo Ventures, then a $53M extension in July 2025 co-led by Radical Ventures and Forerunner Ventures bringing total funding to $93M.

Why Slingshot AI is interesting

Casper co-founder Neil Parikh trains psychology-specific models — a16z led Series A before Forerunner/Radical joined $93M total raise.

Product & use cases

Slingshot trains domain-specific AI models for therapeutic conversation patterns; Ash is the consumer app delivering AI-guided mental health support with clinical advisory oversight.

  • Consumer mental health self-support via Ash app
  • Foundation model licensing for digital health partners
  • AI therapy adjunct between clinical sessions
  • Research on psychology-specific LLM training

Key facts

  • Series A extension (Jul 2025): $53M; total $93M — BusinessWire
  • Series A (Aug 2024): ~$30M led by a16z — a16z announcement
  • Founder Neil Parikh co-founded Casper
  • Ash consumer mental health app + foundation models

Funding history (newest first)

Investors in our directory

Funds linked from Slingshot AI's profile — open a fund page for stage focus and related deal articles.

Competitive landscape

Edge: Purpose-built mental health models vs general ChatGPT wrappers — founder pedigree from Casper consumer scaling.

AI mental health sits between regulated clinical tools and unregulated chatbots. Slingshot bets specialized models + consumer app distribution win; regulatory scrutiny on AI therapy claims is a key risk.

  • Woebot direct

    CBT-based chatbot for mental health; clinical validation focus.

  • Headspace / Calm AI features adjacent

    Meditation apps adding AI coaching.

  • ChatGPT / general LLMs alternative

    Users may use general AI for emotional support without clinical guardrails.

  • Spring Health adjacent

    Employer mental health platform with human + digital care.

Notable stories

  • Parikh pivoted from sleep mattresses (Casper) to AI mental health — applying consumer DTC playbook to regulated-adjacent wellness.
  • a16z led Series A as vertical-specific foundation models became investable category in 2024.

Industries

Healthtech AI & Machine Learning Consumer

FAQs about Slingshot AI

Practical answers founders, operators, and investors typically search for.

Slingshot builds mental-health-specific AI foundation models and offers Ash, a consumer app for AI-guided emotional support.
Andreessen Horowitz (/fund/andreessen-horowitz) led Series A. Forerunner (/fund/forerunner-ventures) and Menlo (/fund/menlo-ventures) joined the 2025 extension.
Slingshot's consumer mental health app using proprietary AI models for guided support conversations.
Neil Parikh (Casper co-founder) and Daniel Cahn.
Both offer AI mental health chat. Woebot has longer clinical research history; Slingshot emphasizes custom foundation models.
Approximately $93M total after July 2025 extension per BusinessWire.
Company positions Ash as support tool, not licensed therapy replacement — check app disclaimers and clinical advisory structure.
August 2024 — led ~$30M Series A.
New York, New York.
We track a16z-backed healthtech and AI companies.

By Venture Capital Tracker

Last updated:

Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.